EUVIMEDEUVIMED entdecken
Crossref

Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration

Mehdi Alami, Hicham Berrougui, Kaoutar Boumezough, Ikram Salih, Khalid Sadki, Benoit Laurent, Olaf van Tellingen, Ton Bunt, Abdelouahed Khalil, Tamas Fulop

Mechanisms of Ageing and Development · 2026

DOI: 10.1016/j.mad.2026.112161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mechanisms of Ageing and Development, 2026. Verfasst von Mehdi Alami und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of Sherbrooke, Faculty of Medicine and Health Sciences, Department of Medicine, Geriatrics Service, Sherbrooke, QC, Canada. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Raltegravir Potassium, Peptide Fragments, Alzheimer Disease. Die Arbeit nennt 58 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Alzheimer Society of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is growing evidence supporting the potential role of microbial infections in the aetiology of Alzheimer's disease (AD) and the protective role of anti-viral therapies. However, not much is known about the molecular mechanisms underlying their effects. We aimed to explore the modulatory role of raltegravir on monomeric amyloid beta 1-42 (m-Aβ1-42)-induced molecular alterations in cellular models of AD. Here we show, using the flow cytometry technique combined with specific monoclonal antibodies, that raltegravir significantly abolishes the m-Aβ1-42-stimulating effect on p-tau 181, and that this effect involves the upregulation of PP2Aα+ β. This effect does not appear to be mediated by GSK-3β and CdK5 modulation, since no significant effect was observed on these kinases. Furthermore, raltegravir treatment significantly reduced CD86 expression without any impact on CD163, suggesting a possible affinity towards reducing the microglia M1-phenotype rather than improving the M2 state. Additionally, raltegravir significantly attenuated IL-1β production, likely through the downregulation of the NLRP3-inflammasome signaling pathway, indicating an important anti-inflammatory activity. Collectively, our in vitro findings are preliminary mechanistic observations that support raltegravir's repurposing for AD, thus soliciting further complementary research, especially in relevant animal models of AD, to accelerate the translation of these findings into the clinical setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesRaltegravir PotassiumPeptide FragmentsAlzheimer DiseaseHIV Integrase InhibitorsHIV-1HumansAnimalsNLR Family, Pyrin Domain-Containing 3 ProteinMicroglia

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid-BetaAntiviral drugsInfectionRaltegravir

Substanzen

Amyloid beta-PeptidesRaltegravir PotassiumPeptide Fragmentsamyloid beta-protein (1-42)HIV Integrase InhibitorsNLR Family, Pyrin Domain-Containing 3 Protein

Autor:innen und Institutionen

  • University of Sherbrooke, Faculty of Medicine and Health Sciences, Department of Medicine, Geriatrics Service, Sherbrooke, QC, Canada.
  • University of Sherbrooke, Faculty of Medicine and Health Sciences, Department of Medicine, Geriatrics Service, Sherbrooke, QC, Canada; Sultan Moulay Sliman University, Polydisciplinary Faculty, Department of Biology, Be…
  • University of Sherbrooke, Faculty of Medicine and Health Sciences, Department of Medicine, Geriatrics Service, Sherbrooke, QC, Canada; Research Laboratory in Oral Biology and Biotechnology, Faculty of Dental Medicine, M…
  • Research Laboratory in Oral Biology and Biotechnology, Faculty of Dental Medicine, Mohammed V University in Rabat, Rabat, Morocco.
  • Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Izumi Biosciences, Inc., Lexington, MA, USA.

Förderung

  • Canadian Institutes of Health Research
  • Alzheimer Society of Canada

Zitieren

APA

Alami, M., Berrougui, H., Boumezough, K., Salih, I., Sadki, K., Laurent, B., van Tellingen, O., Bunt, T., Khalil, A., & Fulop, T. (2026). Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration. Mechanisms of Ageing and Development. https://doi.org/10.1016/j.mad.2026.112161

Vancouver

Alami M, Berrougui H, Boumezough K, Salih I, Sadki K, Laurent B, et al. Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration. Mechanisms of Ageing and Development. 2026. doi:10.1016/j.mad.2026.112161

BibTeX
@article{Alami2026,
  author = {Alami, Mehdi and Berrougui, Hicham and Boumezough, Kaoutar and Salih, Ikram and Sadki, Khalid and Laurent, Benoit and van Tellingen, Olaf and Bunt, Ton and Khalil, Abdelouahed and Fulop, Tamas},
  title = {Antiretroviral raltegravir, a selective human immunodeficiency virus type 1 integrase inhibitor, shows anti-Alzheimer’s potential against amyloid-beta1–42-induced neurodegeneration},
  journal = {Mechanisms of Ageing and Development},
  year = {2026},
  doi = {10.1016/j.mad.2026.112161}
}
Kostenlos starten →